Clonal Hematopoiesis Is Associated With Adverse Clinical Outcomes and Left Ventricular Remodeling in Aortic Stenosis

Chi-Yuan Yao1, Tsung-Yu Ko2, Li-Tan Yang3

  • 1Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan; Department of Laboratory Medicine, National Taiwan University Hospital, Taipei, Taiwan; Graduate Institute of Clinical Medicine, College of Medicine, National Taiwan University, Taipei, Taiwan.

JACC. Advances
|January 31, 2025
PubMed

Insights

Clonal hematopoiesis of indeterminate potential (CHIP) increases heart failure risk in severe aortic stenosis patients after TAVI. CHIP may be an actionable target for AS treatment.

Area of Science:

  • Cardiovascular Medicine
  • Hematology
  • Genetics

Background:

  • Clonal hematopoiesis of indeterminate potential (CHIP) is linked to systemic inflammation and atherosclerotic cardiovascular diseases like aortic stenosis (AS).
  • CHIP is an emerging risk factor for cardiovascular events.

Purpose of the Study:

  • To assess the clinical impact of CHIP in patients with severe AS undergoing transcatheter aortic valve implantation (TAVI).
  • To identify associations between CHIP and clinical, laboratory, and echocardiographic parameters.

Main Methods:

  • Retrospective analysis of 110 severe AS patients undergoing TAVI.
  • Targeted next-generation sequencing to detect CHIP-associated somatic mutations.
  • Multivariate Cox regression analysis to determine the primary endpoint of post-TAVI heart failure hospitalization.

Main Results:

  • CHIP was identified in 36.4% of patients, with DNMT3A, TET2, and ASXL1 as the most common mutations.
  • CHIP was associated with a significantly higher rate of heart failure hospitalization (adjusted HR: 3.060; P = 0.034) over a median follow-up of 55.2 months.
  • CHIP patients exhibited higher serum ferritin, left ventricular hypertrophy, and diastolic dysfunction.

Conclusions:

  • CHIP adversely impacts clinical outcomes in AS patients undergoing TAVI, potentially due to inflammation and maladaptive left ventricular remodeling.
  • Further prospective trials are needed to validate these findings and explore CHIP as a therapeutic target in AS.
Abstract